How Race Can Influence Care Goals and Treatment Decisions in Advanced CancerOctober 3rd 2017
An ongoing study found some differences by ethnicity regarding the importance of factors influencing treatment decisions at end of life, which reinforces the need for EOL communication to be tailored.
Helping Patients Manage Work-Life Balance During and After TreatmentSeptember 28th 2017
During and after treatment, the majority of patients will be back at their jobs sometime after diagnosis and treatment, but that doesn’t have to come with emotional distress if possible outcomes are discussed.
Two Late-Stage Trials Test Novel PI3K Inhibitor in Non-Hodgkin LymphomaSeptember 22nd 2017
Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab (Rituxan)-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma (NHL) in 2 phase III clinical trials that investigators hope will expand treatment options in refractory disease settings, particularly with less toxic alternatives.